Kevin Chu joined F-Prime in 2014 and is currently a Principal on the healthcare investment team based in San Francisco. Prior to F-Prime, Kevin was an Associate Consultant with IMS Consulting Group in New York, where he advised biopharmaceutical clients on development and commercial strategy.

At F-Prime, Kevin focuses primarily on investments in therapeutics, medical devices, and life science tools companies. He was a member of the founding team at Shinobi Therapeutics, led the fund’s investments in Cadence Neuroscience and Amber Therapeutics, and was involved with several legacy fund investments including Innovent Biologics (1801.HK), Semma Therapeutics (acquired by Vertex), Modis Therapeutics (acquired by Zogenix), Farapulse (acquired by Boston Scientific), Cytek Biosciences (NASDAQ: CTKB), and Sipai Health Technology (0314.HK). He also works closely with the Eight Roads Ventures China team to manage F-Prime’s healthcare investment efforts in China.

Kevin holds a B.S.E. from the University of Pennsylvania where he studied Bioengineering and Engineering Entrepreneurship.